miRNA nanotherapeutics for cancer

Aditya Ganju, Sheema Khan, Bilal Hafeez, Stephen W. Behrman, Murali Yallapu, Subhash Chauhan, Meena Jaggi

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) are noncoding RNA molecules that regulate gene expression through diverse mechanisms. Increasing evidence suggests that miRNA-based therapies, either restoring or repressing miRNA expression and activity, hold great promise. However, the efficient delivery of miRNAs to target tissues is a major challenge in the transition of miRNA therapy to the clinic. Cationic polymers or viral vectors are efficient delivery agents but their systemic toxicity and immunogenicity limit their clinical usage. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles (NPs) conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity. Given their importance in clinical oncology, here we focus on the development of miRNA nanoformulations to achieve enhanced cellular uptake, bioavailability, and accumulation at the tumor site.

Original languageEnglish (US)
Pages (from-to)424-432
Number of pages9
JournalDrug Discovery Today
Volume22
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

MicroRNAs
Neoplasms
Untranslated RNA
Medical Oncology
Nanoparticles
Biological Availability
Polymers
Therapeutics
Gene Expression
Peptides
Antibodies

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

miRNA nanotherapeutics for cancer. / Ganju, Aditya; Khan, Sheema; Hafeez, Bilal; Behrman, Stephen W.; Yallapu, Murali; Chauhan, Subhash; Jaggi, Meena.

In: Drug Discovery Today, Vol. 22, No. 2, 01.02.2017, p. 424-432.

Research output: Contribution to journalReview article

@article{fc16bd3f86204768882d3e605b832dc9,
title = "miRNA nanotherapeutics for cancer",
abstract = "MicroRNAs (miRNAs) are noncoding RNA molecules that regulate gene expression through diverse mechanisms. Increasing evidence suggests that miRNA-based therapies, either restoring or repressing miRNA expression and activity, hold great promise. However, the efficient delivery of miRNAs to target tissues is a major challenge in the transition of miRNA therapy to the clinic. Cationic polymers or viral vectors are efficient delivery agents but their systemic toxicity and immunogenicity limit their clinical usage. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles (NPs) conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity. Given their importance in clinical oncology, here we focus on the development of miRNA nanoformulations to achieve enhanced cellular uptake, bioavailability, and accumulation at the tumor site.",
author = "Aditya Ganju and Sheema Khan and Bilal Hafeez and Behrman, {Stephen W.} and Murali Yallapu and Subhash Chauhan and Meena Jaggi",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.drudis.2016.10.014",
language = "English (US)",
volume = "22",
pages = "424--432",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - miRNA nanotherapeutics for cancer

AU - Ganju, Aditya

AU - Khan, Sheema

AU - Hafeez, Bilal

AU - Behrman, Stephen W.

AU - Yallapu, Murali

AU - Chauhan, Subhash

AU - Jaggi, Meena

PY - 2017/2/1

Y1 - 2017/2/1

N2 - MicroRNAs (miRNAs) are noncoding RNA molecules that regulate gene expression through diverse mechanisms. Increasing evidence suggests that miRNA-based therapies, either restoring or repressing miRNA expression and activity, hold great promise. However, the efficient delivery of miRNAs to target tissues is a major challenge in the transition of miRNA therapy to the clinic. Cationic polymers or viral vectors are efficient delivery agents but their systemic toxicity and immunogenicity limit their clinical usage. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles (NPs) conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity. Given their importance in clinical oncology, here we focus on the development of miRNA nanoformulations to achieve enhanced cellular uptake, bioavailability, and accumulation at the tumor site.

AB - MicroRNAs (miRNAs) are noncoding RNA molecules that regulate gene expression through diverse mechanisms. Increasing evidence suggests that miRNA-based therapies, either restoring or repressing miRNA expression and activity, hold great promise. However, the efficient delivery of miRNAs to target tissues is a major challenge in the transition of miRNA therapy to the clinic. Cationic polymers or viral vectors are efficient delivery agents but their systemic toxicity and immunogenicity limit their clinical usage. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles (NPs) conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity. Given their importance in clinical oncology, here we focus on the development of miRNA nanoformulations to achieve enhanced cellular uptake, bioavailability, and accumulation at the tumor site.

UR - http://www.scopus.com/inward/record.url?scp=85006240136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006240136&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2016.10.014

DO - 10.1016/j.drudis.2016.10.014

M3 - Review article

VL - 22

SP - 424

EP - 432

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 2

ER -